SCHEMBL13865282

SCHEMBL13865282

COc1ccc2ncc(C)c(C)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.47
LMNA P02545 2/20 0.46
KDM4E B2RXH2 4/20 0.45
MAPT P10636 1/20 0.45
GRM1 Q13255 1/20 0.45
EGFR P00533 3/20 0.45
GABRA1 P14867 1/20 0.45
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
GABRA2 P47869 1/20 0.45
RIPK2 O43353 1/20 0.45
KDR P35968 1/20 0.45
HTR1A P08908 1/20 0.44
ADRA1D P25100 1/20 0.44
ADRA1A P35348 1/20 0.44
ADRA1B P35368 1/20 0.44
MAPK1 P28482 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24009012 0.82 MAP2K1 (0.56) KDM4EMAPTEGFRNPSR1
SCHEMBL20799508 0.78 KDM4E (0.50) KDM4EMAPTEGFRGABRA1GABRG2
SCHEMBL10259160 0.78 LMNA (0.50) POLBLMNAKDM4EMAPTEGFR
SCHEMBL862347 0.77 CCR1 (0.48) LMNAKDM4EMAPTHTR1AADRA1D
SCHEMBL1496335 0.76 LMNA (0.59) POLBLMNAKDM4EMAPTGRM1
SCHEMBL2946799 0.75 LMNA (0.43) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL5706839 0.75 CYP17A1 (0.44) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL4854355 0.75 LMNA (0.43) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL12779098 0.73 MAPT (0.58) LMNAKDM4EMAPTGRM1EGFR
SCHEMBL24010126 0.72 GABRA1 (0.45) KDM4EEGFRGABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity ASTRAZENECA AB (SE) 2009-05-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131444-A1 Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity AAAS, AMPD2, AMPD3 POLB 731/4885LMNA 4199/4885KDM4E 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.